论文部分内容阅读
目的探讨雄激素受体(AR)在人Luminal B型乳腺癌中的表达情况及其与临床特征间关系。方法选取76例Luminal B型乳腺癌患者病理标本,应用免疫组织化学方法检测AR表达情况,同时分析AR的表达与乳腺癌患者年龄、绝经与否、肿瘤大小、淋巴结转移、组织分级、临床分期及Her-2的关系。结果 76例Luminal B型乳腺癌患者中,AR表达阳性的患者54例,阳性率为71.1%。AR阳性表达率在年龄、肿瘤直径、是否绝经、组织学分级、Her-2是否阳性中差异均无统计学意义(P﹥0.05)。不同TNM分期肿瘤患者AR表达情况不同,差异有统计学意义(P﹤0.05)。结论 AR在Luminal B型乳腺癌中具有较高的表达率,且其与肿瘤临床分期有关,AR可能为Luminal B型乳腺癌的治疗提供新的靶点。
Objective To investigate the expression of androgen receptor (AR) in human Luminal B type breast cancer and its relationship with clinical features. Methods 76 patients with Luminal B breast cancer were selected for pathological examination. The expression of AR was detected by immunohistochemistry. The expression of AR was analyzed with age, menopause or not, tumor size, lymph node metastasis, histological grade, clinical stage, Her-2’s relationship. Results Of the 76 patients with Luminal B breast cancer, 54 patients were positive for AR expression, the positive rate was 71.1%. There was no significant difference in the positive expression rate of AR in age, tumor diameter, whether or not menopause, histological grading, and whether Her-2 was positive (P> 0.05). The expression of AR in different TNM staging patients was different, the difference was statistically significant (P <0.05). Conclusion AR has high expression rate in Luminal B and its clinical staging. AR may provide a new target for the treatment of Luminal B breast cancer.